Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase

Letizia Crocetti, Igor A. Schepetkin, Agostino Cilibrizzi, Alessia Graziano, Claudia Vergelli, Donatella Giomi, Andrey Ivanovich Khlebnikov, Mark T. Quinn, Maria Paola Giovannoni

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

Original languageEnglish
Pages (from-to)6259-6272
Number of pages14
JournalJournal of Medicinal Chemistry
Volume56
Issue number15
DOIs
Publication statusPublished - 8 Aug 2013
Externally publishedYes

Fingerprint

Secretory Proteinase Inhibitory Proteins
Leukocyte Elastase
Inhibitory Concentration 50
Indazoles
Ligands
Serine Proteases
Lung Diseases
Protons
Peptide Hydrolases
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Crocetti, L., Schepetkin, I. A., Cilibrizzi, A., Graziano, A., Vergelli, C., Giomi, D., ... Giovannoni, M. P. (2013). Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase. Journal of Medicinal Chemistry, 56(15), 6259-6272. https://doi.org/10.1021/jm400742j

Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase. / Crocetti, Letizia; Schepetkin, Igor A.; Cilibrizzi, Agostino; Graziano, Alessia; Vergelli, Claudia; Giomi, Donatella; Khlebnikov, Andrey Ivanovich; Quinn, Mark T.; Giovannoni, Maria Paola.

In: Journal of Medicinal Chemistry, Vol. 56, No. 15, 08.08.2013, p. 6259-6272.

Research output: Contribution to journalArticle

Crocetti, L, Schepetkin, IA, Cilibrizzi, A, Graziano, A, Vergelli, C, Giomi, D, Khlebnikov, AI, Quinn, MT & Giovannoni, MP 2013, 'Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase', Journal of Medicinal Chemistry, vol. 56, no. 15, pp. 6259-6272. https://doi.org/10.1021/jm400742j
Crocetti, Letizia ; Schepetkin, Igor A. ; Cilibrizzi, Agostino ; Graziano, Alessia ; Vergelli, Claudia ; Giomi, Donatella ; Khlebnikov, Andrey Ivanovich ; Quinn, Mark T. ; Giovannoni, Maria Paola. / Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase. In: Journal of Medicinal Chemistry. 2013 ; Vol. 56, No. 15. pp. 6259-6272.
@article{41791920e31a42adbbfdc7b2a0a50798,
title = "Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase",
abstract = "Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.",
author = "Letizia Crocetti and Schepetkin, {Igor A.} and Agostino Cilibrizzi and Alessia Graziano and Claudia Vergelli and Donatella Giomi and Khlebnikov, {Andrey Ivanovich} and Quinn, {Mark T.} and Giovannoni, {Maria Paola}",
year = "2013",
month = "8",
day = "8",
doi = "10.1021/jm400742j",
language = "English",
volume = "56",
pages = "6259--6272",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase

AU - Crocetti, Letizia

AU - Schepetkin, Igor A.

AU - Cilibrizzi, Agostino

AU - Graziano, Alessia

AU - Vergelli, Claudia

AU - Giomi, Donatella

AU - Khlebnikov, Andrey Ivanovich

AU - Quinn, Mark T.

AU - Giovannoni, Maria Paola

PY - 2013/8/8

Y1 - 2013/8/8

N2 - Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

AB - Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

UR - http://www.scopus.com/inward/record.url?scp=84881450780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881450780&partnerID=8YFLogxK

U2 - 10.1021/jm400742j

DO - 10.1021/jm400742j

M3 - Article

VL - 56

SP - 6259

EP - 6272

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -